Madrigal Pharma CEO talks competition in the liver disease treatment space

Key Concepts

• MASH (Metabolic Dysfunction-Associated Steatohepatitis): A serious liver disease linked to obesity and metabolic issues.
• Resmetirom (Rezdiffra): The first MASH drug cleared by the FDA, developed by Madrigal Pharmaceuticals.
• Market Penetration: The percentage of the total addressable market that a company has captured.
• Specialty Market: A market segment characterized by a specific group of healthcare providers and patients.
• Run Rate: An annualized projection of revenue based on current performance.

MASH Drug Market: A Growing Landscape

The pharmaceutical industry is making significant investments in drugs targeting MASH, a liver disease associated with obesity and metabolic disorders. This year has seen several major pharmaceutical companies, including Roach and Novo Nordisk, acquire companies focused on liver disease, with potential deal values reaching billions of dollars. These strategic moves are a direct response to the successful launch of Madrigal Pharmaceuticals' Rezdiffra (resmetirom), which received FDA clearance in March 2024, marking the first MASH drug to be approved.

Madrigal Pharmaceuticals' Perspective on Market Dynamics

Bill Cibil, CEO of Madrigal Pharmaceuticals, shared insights into the evolving MASH treatment landscape. He emphasized that the entry of more competitors is beneficial, as it drives awareness and treatment for MASH. Cibil stated, "Having more entrants is really helpful. It drives awareness, treatment and ultimately with the profile of product that we have with reser it helps us overall."

Regarding physician adoption and competitive positioning, Cibil indicated that there has been no significant change in physician indications of interest since the launch of Rezdiffra. He views the MASH market as having ample room for multiple players.

Market Size and Growth Potential

Cibil highlighted the substantial market potential for MASH treatments:

• Diagnosed Patients in the US: Approximately 315,000.
• Patients on Madrigal's Drug (Rezdiffra) in the last quarter: Over 23,000.
• Current Market Penetration: 7% of diagnosed patients.
• Estimated Diagnosis Rate: Around 10%.

This data suggests a significant number of undiagnosed prevalent patients, indicating substantial market development opportunities. Cibil drew parallels to other specialty markets like rheumatoid arthritis and psoriasis, which, 25 years after their first drug launches, have over 15 products and exceed $20 billion in value.

Madrigal Pharmaceuticals reported an $800 million run rate in the last quarter, underscoring the early stage of market development with only 7% penetration. Cibil believes that more companies entering the space will further drive diagnosis and treatment.

Competitive Strategy and Positioning

Madrigal Pharmaceuticals is confident in its ability to compete against larger pharmaceutical companies with substantial marketing budgets. Cibil stated, "Look, in my career, I've competed against the the biggest of big. Uh, that doesn't scare me at all. Doesn't scare us at all."

Their competitive advantage is attributed to:

• Strong Product Profile: Rezdiffra's efficacy and safety.
• Experienced Team: A team with a proven track record of scaling companies and products.
• Specialty Market Focus: MASH patients are treated by specialists (hepatologists, gastroenterologists, endocrinologists), allowing Madrigal's size to effectively target this niche.

Cibil asserted that Madrigal's launch metrics are "tracking at or near the top of every metric" when compared to the 10 best specialty launches in the last decade, deeming it an "objectively outstanding launch." He believes that by the time competitors enter, Madrigal will have treated tens of thousands more patients, establishing a significant lead.

Future Outlook and Collaboration

Madrigal Pharmaceuticals welcomes new entrants to the MASH market, viewing them as contributors to overall market growth. Cibil concluded, "No, we're happy to have them here and we wish them good luck."

Synthesis/Conclusion

The MASH drug market is poised for significant growth, driven by increasing awareness and the unmet medical need. Madrigal Pharmaceuticals, with its first-mover advantage and strong product profile, is well-positioned to lead this emerging specialty market. While larger competitors are entering the space, Madrigal remains confident in its ability to compete effectively due to its focused strategy and experienced team. The market's early stage and substantial undiagnosed patient population suggest ample opportunity for multiple successful treatments.